How Can We Help You?

Tag Archives: National Institute on Drug Abuse (NIDA)

Senior Associates at Bizzell Co-author NIDA Report on Improving Adolescent Health

Senior Associates at Bizzell Co-author NIDA Report on Improving Adolescent Health

According to numerous reports, it takes roughly 17 years [1] for research findings to find their way into routine clinical practice, depriving adults, and children of timely and effective therapeutic care. The improvement of adolescent health ultimately depends on access to timely research and scientific findings from the National Institute on Drug Abuse (NIDA) to better educate health care professionals, policymakers, adolescents, and their families. The “National Institute of Drug Abuse: Dissemination of Scientific Knowledge to Improve Adolescent Health” report spotlights NIDA’s vigorous efforts to accomplish the dissemination of evidence-based information achieved through varying approaches to diverse and targeted audiences; more specifically on substance use disorders (SUD) in the adolescent population.

The NIDA Clinical Trials Network Dissemination Initiative contract, held by Bizzell US, is overseen by co-authors Dr. Todd Mandell and Kenyatta Crenshaw. Within the report, the co-authors share evidence-based educational resources and materials developed to reduce the persistent gap between the publication of research findings on the treatment of SUDs and best practices for implementation and adoption in clinical practice. Dr. Mandell and Ms. Crenshaw also address the Mentor Facilitated Training Program (MFT), which is part of the NIDA Clinical Trials Network Dissemination Initiative contract. An overview of the MFT program is provided in the article, demonstrating how trainees in the field of substance use are encouraged to expand their depth of knowledge by the 1) identification of gaps in substance abuse training; and 2) dissemination of NIDA-sponsored, evidence-based resources/tools to their peers. The study was published in the Child and Adolescent Psychiatric Clinics of North American Volume 32, Issue 1, January 2023.

“I would like to congratulate Dr. Mandell and Ms. Crenshaw, and the other contributing authors, on the publication of the report, the recommendations are another imperative step to ensuring that the dissemination and access to critical data and tools is widely accessible to the public health community” said Anton C. Bizzell, MD, Chairman & CEO of Bizzell.

[1] Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med 2011;104(12): 510–20. Accessed December 14, 2021.

About Bizzell US

Established in 2010, Bizzell US is a U.S. Small Business Administration (SBA) HUBZone-certified strategy, consulting, and technology firm with a mission to improve lives and accelerate change. Bizzell US develops innovative solutions to some of the most critical issues of our time such as health care services equity, global health, workforce innovation, and other urgent needs facing the world. Under the leadership and vision of founder, Anton C. Bizzell, MD, the company has grown into a thriving firm, headquartered in New Carrollton, Maryland, with staff and offices in various regions around the country, including California, Colorado, Connecticut, Oklahoma, and Georgia, and globally in Africa, Asia, and Central America. Learn more about how we develop data-driven, research-informed, innovative solutions to complex, real-world challenges. Learn more at www.BizzellUS.com

Utilizing Behavioral Therapy to Address Stimulant Use Disorder

Utilizing Behavioral Therapy to Address Stimulant Use Disorder

Bizzell US, in partnership with The University of Vermont’s Center on Rural Addiction has produced an interactive educational video for clinicians and practitioners highlighting Contingency Management options for addressing stimulant use disorders.

With rural stimulant overdoses now higher than in urban counties (6.7 vs 4.8 per 100,000.)[1], a renewed focus on combating addiction within these remote communities has taken on a new sense of urgency. “This video adds an important, well studied tool for addressing stimulant use disorder,” said Dr. Todd Mandell of Bizzell US who specializes in substance use and mental health and who was the lead producer of the educational video.

According to the Centers for Disease Control and Prevention (CDC), in 2018, 40% of all overdose deaths were attributed to stimulate use. Until recently there have not been medical treatment alternatives for practitioners treating patients with stimulant use disorder which makes the use of Contingency Management even more urgent.

The video highlights the history of the development of Contingency Management and stresses the key components of a successful program.

To view the educational video please visit: http://uvmcm.modernepic.net

[1] Hedegaard H, Spencer MR. Urban–rural differences in drug overdose death rates, 1999–2019. NCHS Data Brief, no 403. Hyattsville, MD: National Center for Health Statistics. 2021. DOI: https://dx.doi.org/10.15620/cdc:102891

Mobile Clinics Tested as a Way to Treat Substance Use Disorders

Mobile Clinics Tested as a Way to Treat Substance Use Disorders

Mobile health units may be able to help manage HIV infections and opioid use disorder. A clinical trial, funded by the National Institute of Allergy and Infectious Diseases and the National Institute on Drug Abuse, aims to determine mobile clinics’ effectiveness and usefulness in opioid use disorder treatment. The clinical trial will have 860 participants, for 26 weeks and in five cities—Los Angeles, New York, Houston, Philadelphia and Washington, DC.  Researchers will evaluate whether these mobile health units will help people to treat opioid use disorder and prevent or receive care for HIV/AIDS.

“If they have HIV/AIDS, it can then be transferred to another person,” said Anton C. Bizzell, MD, a physician who advocates for addressing healthcare disparities and the chief executive order of the Bizzell Group, tells Verywell. “It’s also important to know that we can decrease the incidence of substance abuse, as well as infections that can occur.” People may be reluctant to access appropriate health care due to stigma and cost. Dr. Bizzell states that if you take the mobile clinics to where people live and work, they are more likely to receive care.

Read more: NIH-Funded Study Tests Mobile Clinics as a Way to Treat Substance Abuse

Image Source: Métraux, J. (2021). Verywell/LifeLineMobile [Online Picture]. Verywell Health. https://www.verywellhealth.com/study-investigates-if-mobile-clinics-will-help-people-with-opioid-use-disorder-5190855

Bizzell Supports Nida in the Launch of Innovative Learning Tools to Help Manage Opioid Treatment

Bizzell Supports Nida in the Launch of Innovative Learning Tools to Help Manage Opioid Treatment

In conjunction with the National Institute on Drug Abuse-Clinical Trials Network (NIDA-CTN), Bizzell announces the availability of three educational videos for healthcare providers managing opioid use disorder (OUD). The first two videos are animations that discuss overdose prevention. The third video is an interactive tool used to educate healthcare providers on OUD in an emergency setting.

Video 1Overdose Prevention Education for Clinicians Treating Patients with Opioids for Chronic Pain  is an animated video that focuses on four key strategies: Reducing Risk for Development of OUD and Avoidance of Misuse, Identification of Risk Factors, Safety Planning, and Overdose Rescue Preparation.

Video 2: Overdose Prevention Education for Clinicians Treating Patients for an Opioid Use Disorder is an animated video that highlights three key strategies: Identifying Overdose Risk Factors, Developing a Safety Plan, and Overdose Rescue Preparation.

“These teachings are done in a simple, non-judgmental fashion offering the viewer clear and memorable points in assessing and managing opioid overdoses,” says Douglas L. Gourlay, M.D., MSc., FRCPC, FASAM, Former Director of the Pain and Chemical Dependency division of the Wasser Pain Management Centre at Mount Sinai Hospital in Toronto, a reviewer of the video.

Video  3:  Buprenorphine  Initiation   for   Opioid   Use   Disorders   in   Emergency Departments:Interactive Case Vignettes  is a branching video, which is an interactive educational tool. It allows participants to select a healthcare track which results in varying outcomes. The American College of Emergency Physicians (ACEP) is providing Continuing Medical Education (CME) credit and access to the tool will require the creation of a free     ACEP account. Throughout the course, guidance is provided on the clinical management of OUD with a focus on screening, enlisting the patient’s input  into  their  treatment,  buprenorphine initiation, and referral to ongoing treatment.

After watching these videos, participants will be able to apply a patient-centered, shared decision-making approach while discussing the prevalence of overdose and the process of introducing buprenorphine in the ED for treatment of OUD. Participants will also be able to discuss chances for recovery as research suggests that patients are twice as likely to enter addiction treatment and remain in treatment at 30 days if medication is initiated in the ED.

The targeted audiences for the buprenorphine initiation video include: Emergency Physicians, Emergency Nurses, Nurse Practitioners, Residents, Medical Students, Physician Assistants, Emergency Department Medical Directors, Hospital Administrators, EMTs/Paramedics, and other healthcare providers engaged in the practice of emergency medicine.

“This branching video effectively and quickly walks users through the most high-yield information in the most engaging way possible. Providers around the country should see this video before their next shift caring for patients with opioid addiction,” says video reviewer, Alister Martin MD, MPP, Faculty – Center for Social Justice and Health Equity, Harvard Medical School, Massachusetts General Hospital Emergency Department.

All of the above mentioned videos were funded in part with federal funds from the National Institute on Drug Abuse, Center for the Clinical Trials Network Dissemination Initiative (contract # HHSN271201700059C). The content for the videos was developed by researchers and experts and does not necessarily reflect the official position of the National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. These training resources should not be considered as a substitute for individualized patient care and treatment decisions.

  • This activity has been planned and implemented in accordance with the accreditation requirements and policies of The Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians, NIDA, The Bizzell Group, and Modern Epic. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.
  • The  American College of Emergency Physicians designates this enduring material activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate .with the extent of their participation in the activity.
  • Approved by the American College of Emergency Physicians for 1 hour of ACEP Category I credit.

ABOUT BIZZELL

Established in 2010, The Bizzell Group (Bizzell) is a U.S. Small Business Administration (SBA) 8(a) certified strategy, consulting, and technology firm that specializes in program management, administrative support, communications and outreach, conference management and logistical support, health services and research, technical assistance, and training and development. Bizzell’s expert staff and consultants work on health, scientific, education, environmental, research, and information technology projects that advance national priorities. Under the leadership and vision of founder, Anton C. Bizzell, MD, the company has grown from a staff of two in one small office, to a thriving firm with three offices in Lanham, MD, Rockville, MD, and Atlanta, GA, with ongoing projects around the world. Learn more about how we develop data- driven, research-informed, innovative solutions to complex-real-world challenges: www.BizzellUS.com.

ABOUT THE NATIONAL INSTITUTE ON DRUG ABUSE (NIDA)

The National Institute on Drug Abuse (NIDA) is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. Fact sheets on the health effects  of  drugs  and  information  on   NIDA  research  and   other   activities   can  be  found at www.drugabuse.gov, which is now compatible with your smartphone, iPad or tablet. To order publications in English or Spanish, call NIDA’s DrugPubs research dissemination center at 1-877- NIDA-NIH or 240-645-0228 (TDD) or email requests to drugpubs@nida.nih.gov. Online ordering is    available    at drugpubs.drugabuse.gov.     NIDA’s     media     guide     can     be     found   at www.drugabuse.gov/publications/media-guide/dear-journalist, and its easy-to-read website can be found at www.easyread.drugabuse.gov. You can follow NIDA on Twitter and Facebook.